Invivoscribe Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics and personalized molecular medicine , today released three additional CE-marked next-generation sequencing assay kits for in vitro diagnostic use to assist in the diagnosis of B-cell malignancies. Invivoscribe has now commercialized more than 40 CE-IVD assays and bioinformatics packages for capillary electrophoresis and NGS platforms and has recently announced a long-term agreement with Thermo Fisher Scientific to bring regulated IVD assays through the FDA on the Ion PGM Dx System.
Category: Excelerate Labs
Cell Expansion Market Is Worth USD 7.96 Billion in 2016 and Is…
According to the new market research report, ” Cell Expansion Market , by Products , Cells Types , Applications , End-users – Global Revenue, Trends, Growth, Share, Size and Forecast to 2022″, published by Scalar Market Research, the global cell expansion market is expected to reach USD 18.74 billion by 2022, growing at a CAGR of 15.30% from 2016 to 2022. According to the report, the market is expected to be worth USD 7.96 billion in the year 2016.